Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials.
Winnie YeoNicole T Y NgaiChristopher C H YipFrankie K F MoVictoria A YeoJonathan W H KoLeung V LiThomas K H LauKwai Tung LaiElizabeth PangClaudia H W YipHoratio L YeoCarol Chi Hei KwokStephanie W Y KoAlex MolassiotisPublished in: Cancer management and research (2024)
The present study confirmed previously reported risk factors for CINV in Chinese breast cancer patients receiving doxorubicin and cyclophosphamide. Further optimization of CINV control is required for patients with identifiable risk factors; olanzapine/aprepitant- or NEPA- containing prophylaxis are the preferred contemporary anti-emetics regimens for Chinese breast cancer patients undergoing doxorubicin and cyclophosphamide chemotherapy.